Weill Cornell Medicine (WCM) SPORE in Prostate Cancer

总体汇总 前列腺癌（PCA）是西半球最常见的癌症之一，具有极端的临床表现。 和分子异质性。2015年，超过221，800名男性被诊断患有PCA，27，540人死于PCA。 美国的我们的威尔康奈尔医学（WCM）孢子在PCA将采取一种新颖的精准医学 病人护理的方法，这将使我们的转化研究目标与整个PCA的男性护理保持一致 江西篇章尽早检测侵袭性PCA将避免效果较差的晚期治疗。我们 将研究如何改善局部PCA男性的风险评估，以实现最佳治疗选择， 主动监视（Active Surveillance，AS）晚期PCA男性，尽管接受了下一代雄激素治疗 剥夺疗法（ADT），屈服于耐药性和疾病进展。我们需要优化护理 通过新的生物标志物和治疗策略，将致命的PCA转变为一种可控制的慢性疾病。 我们注意到其他领域的知识可以增强我们的研究。我们会积极利用 发展研究计划将来自丰富的多机构环境的研究人员带到 专注于PCA翻译研究。一个可持续的SPORE计划需要发展的职业生涯， 初级教师（职业提升计划），谁将在该领域的领导者在未来几年。水平 垂直科学合作将确保我们利用其他领域的专业知识和经验， SPOREs、早期检测研究网络（EDRN）、Stand Up 2 Cancer（SU2C）和前列腺 癌症基金会（PCF）计划。最后，我们将确保我们的研究所产生的资源和数据 将提供给研究界。我们的首要目标是从最初的PCA护理 通过使用精确医学方法管理晚期疾病进行诊断， 目前的临床护理。 总之，PCA中的WCM SPORE将成为范式转换翻译研究的主要中心。我们将 建立治疗PCA的新方法，这将导致改善患者生存和生活质量。

OVERALL SUMMARY Prostate cancer (PCA) is one of the most common cancers in the Western hemisphere, with extreme clinical and molecular heterogeneity. In 2015, over 221,800 men were diagnosed with—and 27,540 died from—PCA in the United States. Our Weill Cornell Medicine (WCM) SPORE in PCA will take a novel precision medicine approach to patient care, which will align our translational research goals with the care of men across the PCA spectrum. The earliest possible detection of aggressive PCA will avoid less effective late-stage therapies. We will study how to improve risk assessment in men with localized PCA to enable optimal treatment choices, including active surveillance (AS). Men with advanced PCA, despite treatment with next generation androgen deprivation therapy (ADT), succumb to drug resistance and disease progression. We need to optimize care through novel biomarker and treatment strategies to change lethal PCA to a chronic manageable disease. We are mindful that knowledge from other fields can augment our research. We will actively use the Developmental Research Program to bring investigators from across a rich, multi-institutional landscape to focus on PCA translational research. A sustainable SPORE program requires development of the careers of junior faculty (Career Enhancement Program), who will be the leaders in the field for years to come. Horizontal and vertical scientific collaborations will ensure that we leverage expertise and experience across other SPOREs, the Early Detection Research Network (EDRN), and the Stand Up 2 Cancer (SU2C) and Prostate Cancer Foundation (PCF) programs. Lastly, we will ensure that resources and data generated from our studies will be made available to the research community. Our overarching goal is to impact PCA care from initial diagnosis through management of advanced state disease using precision medicine approaches to improve current clinical care. In summary, the WCM SPORE in PCA will be a major hub for paradigm-shifting translational research. We will establish new approaches to treating PCA, which will result in improved patient survival and quality of life.